VivaQuant

Executive Summary

VivaQuant is a US-based digital health company specializing in advanced ECG analysis software for cardiac arrhythmia detection and monitoring. Founded in 2010 and headquartered in St. Paul, Minnesota, the company markets its technology under the RhythmExpress ECG brand. VivaQuant's core offering consists of sophisticated algorithms designed to improve the accuracy and efficiency of heart rhythm analysis, primarily for clinical and ambulatory settings. By leveraging signal processing and machine learning, the company aims to enhance the detection of arrhythmias such as atrial fibrillation, which affects millions worldwide. Its software can be integrated into existing ECG devices and workflows, potentially reducing the burden on clinicians and enabling earlier diagnosis. Despite a lack of publicly disclosed funding rounds or revenue figures, VivaQuant operates in a growing market for remote cardiac monitoring and digital diagnostics. The increasing adoption of wearable devices and telehealth, coupled with an aging population, drives demand for scalable arrhythmia detection solutions. VivaQuant's algorithms could be differentiated by their claimed accuracy and low false-positive rates. However, the company faces competition from established players like AliveCor, iRhythm, and GE Healthcare. Success will depend on securing regulatory clearances, forming strategic partnerships with device manufacturers or healthcare systems, and demonstrating clinical utility through peer-reviewed studies or real-world evidence.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for updated RhythmExpress algorithm with AI-enhanced detection70% success
• Q4 2026Partnership agreement with a major U.S. hospital network for remote monitoring pilot50% success
• Q1 2027Publication of clinical validation study in a peer-reviewed cardiology journal60% success